logo
Overview
Discover
Watchlists
Portfolios
Heatmap
Sectors
Trendscore
Performers
Alerts
Options
Earnings
Screeners
Scanners
Backtests
Strategies
Comparisons
Charts
Sign in
Discover
SNTI
Senti Biosciences, Inc.
0.46
1 x 0.46
2 x 0.48
bid
ask
+
0.03
6.13%
1 @ 04:00 PM
0.46 -0.00 (0.09%)
Ytd-55.73%
1y-76.75%
0.43
day range
0.51
0.42
52 week range
2.88
Open0.50Prev Close0.43Low0.43High0.51Mkt Cap12.10M
Vol651.01KAvg Vol255.86KEPS-1.99P/E-0.23Forward P/E-5.33
Beta2.04Short Ratio3.27Inst. Own23.33%DividendN/ADiv YieldN/A
Ex Div DateN/AEarning08-1850-d Avg0.94200-d Avg1.211yr Est12.00

SNTI News

12 Health Care Stocks Moving In Thursday's Intraday Session
benzinga.com
12 Health Care Stocks Moving In Thursday's Intraday Session

Gainers Liminatus Pharma (NASDAQ:LIMN) stock moved upwards by 55.6% to $0.18 during Thursday's

12 Health Care Stocks Moving In Wednesday's Intraday Session
benzinga.com
12 Health Care Stocks Moving In Wednesday's Intraday Session

Gainers China Pharma Holding (AMEX:CPHI) shares moved upwards by 67.6% to $1.03 during Wednesday&#3
benzinga.com
Senti Biosciences Signs Agreement To Sell Assets Related To Its Gene-Circuit-Enabled Pipeline To Cel

Senti Biosciences Holdings, Inc. (NASDAQ: SNTI) ("SBH" or the "Company") today annou

Senti Biosciences Holdings, Inc. Announces a Strategic Transaction to Unlock Value for its Gene-Circuit-Enabled Pipeline, Including SENTI-202, and to Sharpen its Focus on Next-Generation Controllable Genetic Medicines Powered by its Regulator Dial™ Technology Platform
globenewswire.com
Senti Biosciences Holdings, Inc. Announces a Strategic Transaction to Unlock Value for its Gene-Circ

SOUTH SAN FRANCISCO, Calif., July 15, 2026 (GLOBE NEWSWIRE) -- Senti Biosciences Holdings, Inc. (NAS

Senti Biosciences Holdings Reports First Quarter 2026 Financial Results and Highlights Advancement of SENTI-202 Program into Pivotal Phase
globenewswire.com
Senti Biosciences Holdings Reports First Quarter 2026 Financial Results and Highlights Advancement o

Secured strategic financing vehicle for up to $40 million Positive FDA feedback supports single-arm

Senti Biosciences Holdings Announces Positive FDA RMAT Meeting on Registrational Clinical and CMC Strategy for SENTI-202 in Relapsed/Refractory AML, Along with Important Efficacy and Durability Updates on the SENTI-202 Clinical Program
globenewswire.com
Senti Biosciences Holdings Announces Positive FDA RMAT Meeting on Registrational Clinical and CMC St

Following a Type B meeting with FDA, Senti Bio plans to proceed with a single-arm multi-center regis

Senti Biosciences to Present on Logic-Gated Cell Therapies in Educational Session at AACR Annual Meeting 2026
globenewswire.com
Senti Biosciences to Present on Logic-Gated Cell Therapies in Educational Session at AACR Annual Mee

SOUTH SAN FRANCISCO, Calif., April 13, 2026 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. (Nasdaq: SNT

Senti Biosciences Announces Publication in Cell Systems Demonstrating Advanced Logic-Gated CAR Design for Cell Therapies
globenewswire.com
Senti Biosciences Announces Publication in Cell Systems Demonstrating Advanced Logic-Gated CAR Desig

SOUTH SAN FRANCISCO, Calif., April 01, 2026 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. (Nasdaq: SNT

Senti Bio Reports Fourth Quarter and Full Year 2025 Financial Results and Provides a Corporate Update
globenewswire.com
Senti Bio Reports Fourth Quarter and Full Year 2025 Financial Results and Provides a Corporate Updat

SOUTH SAN FRANCISCO, Calif., March 27, 2026 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. (Nasdaq: SNT

Senti Biosciences, Inc. (NASDAQ:SNTI) Given Average Rating of “Moderate Buy” by Brokerages
defenseworld.net
Senti Biosciences, Inc. (NASDAQ:SNTI) Given Average Rating of “Moderate Buy” by Brokerages

Shares of Senti Biosciences, Inc. (NASDAQ: SNTI - Get Free Report) have received an average rating o

Senti Biosciences to Present Clinical and Translational Data on SENTI-202 at the 11th Annual Innate Killer Conference
globenewswire.com
Senti Biosciences to Present Clinical and Translational Data on SENTI-202 at the 11th Annual Innate

SOUTH SAN FRANCISCO, Calif., March 23, 2026 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. (Nasdaq: SNT

Senti Biosciences to Present at Leerink Partners 2026 Global Healthcare Conference
globenewswire.com
Senti Biosciences to Present at Leerink Partners 2026 Global Healthcare Conference

SOUTH SAN FRANCISCO, Calif., March 03, 2026 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. (Nasdaq: SNT

Senti Biosciences, Inc. (NASDAQ:SNTI) Given Consensus Recommendation of “Moderate Buy” by Analysts
defenseworld.net
Senti Biosciences, Inc. (NASDAQ:SNTI) Given Consensus Recommendation of “Moderate Buy” by Analysts

Senti Biosciences, Inc. (NASDAQ: SNTI - Get Free Report) has been given an average rating of "Modera

Senti Biosciences to Present at TD Cowen 46th Annual Health Care Conference
globenewswire.com
Senti Biosciences to Present at TD Cowen 46th Annual Health Care Conference

SOUTH SAN FRANCISCO, Calif., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. (Nasdaq: SNTI

Senti Bio Participates in Cell & Gene Live Event Highlighting Cutting-Edge Technologies Advancing Cell Therapy Development
globenewswire.com
Senti Bio Participates in Cell & Gene Live Event Highlighting Cutting-Edge Technologies Advancing Ce

SOUTH SAN FRANCISCO, Calif., Feb. 20, 2026 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. (Nasdaq: SNTI

12 Health Care Stocks Moving In Thursday's Pre-Market Session
benzinga.com
12 Health Care Stocks Moving In Thursday's Pre-Market Session

Senti Biosciences Completes Enrollment in Phase 1 Clinical Trial of SENTI-202 for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia (R/R AML)
globenewswire.com
Senti Biosciences Completes Enrollment in Phase 1 Clinical Trial of SENTI-202 for the Treatment of R

Robust SENTI-202 clinical data presented at ASH 2025 demonstrated deep, MRD-negative, durable comple

Senti Biosciences Selected for On-Stage Presentation at Healthcare Conference Taipei 2026
globenewswire.com
Senti Biosciences Selected for On-Stage Presentation at Healthcare Conference Taipei 2026

SOUTH SAN FRANCISCO, Calif., Feb. 03, 2026 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. (Nasdaq: SNTI

Senti Biosciences Participates in Virtual Investor CEO Connect Segment to Discuss the Company's Groundbreaking AML Data at the American Society of Hematology Annual Meeting and Recently Granted RMAT Designation
globenewswire.com
Senti Biosciences Participates in Virtual Investor CEO Connect Segment to Discuss the Company's Grou

Access the segment  here

Senti Bio to Participate in Panel Presentation at Biotech Showcase Alongside the J.P. Morgan Annual Healthcare Conference
globenewswire.com
Senti Bio to Participate in Panel Presentation at Biotech Showcase Alongside the J.P. Morgan Annual

SOUTH SAN FRANCISCO, Calif., Jan. 09, 2026 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. (Nasdaq: SNTI

Senti Biosciences Announces New Employment Inducement Grants
globenewswire.com
Senti Biosciences Announces New Employment Inducement Grants

SOUTH SAN FRANCISCO, Calif., Dec. 18, 2025 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. (Nasdaq: SNTI

Senti Biosciences, Inc. (NASDAQ:SNTI) Receives Average Rating of “Moderate Buy” from Analysts
defenseworld.net
Senti Biosciences, Inc. (NASDAQ:SNTI) Receives Average Rating of “Moderate Buy” from Analysts

Senti Biosciences, Inc. (NASDAQ: SNTI - Get Free Report) has been given an average recommendation of

Senti Bio Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for SENTI-202 in the Treatment of Adults with Relapsed or Refractory Acute Myeloid Leukemia
globenewswire.com
Senti Bio Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for SENTI-202 in th

RMAT designation indicates that SENTI-202 has the potential to address unmet medical needs for patie

Senti Bio Announces Updated SENTI-202 Clinical Data from Ongoing Phase 1 Trial in Relapsed or Refractory Acute Myeloid Leukemia Patients, Demonstrating Deep, MRD Negative, Durable Complete Remissions and a Favorable Safety Profile
globenewswire.com
Senti Bio Announces Updated SENTI-202 Clinical Data from Ongoing Phase 1 Trial in Relapsed or Refrac

ASH 2025 oral presentation on SENTI-202 in 20 Relapsed/Refractory Acute Myeloid Leukemia (R/R AML) p
benzinga.com
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
benzinga.com
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
benzinga.com
Stocks That Hit 52-Week Lows On Monday

  Monday saw 825 companies set new 52-week lows.
benzinga.com
Stocks That Hit 52-Week Lows On Wednesday

  On Wednesday, 340 stocks hit new 52-week lows.
benzinga.com
Why Virios Therapeutics Is Trading Lower By 75%, Here Are 44 Stocks Moving In Tuesday's Mid-Day Sess

Gainers Crown ElectroKinetics Corp. (NASDAQ: CRKN) shares jumped 51% to $0.4957. Crown ElectroKin
benzinga.com
Why Aditxt Shares Dipped Over 58%; Here Are 82 Biggest Movers From Friday

Gainers Panbela Therapeutics, Inc. (NASDAQ: PBLA) shares jumped 53% to close at $0.58 on Friday.

benzinga.com
Why Lottery.com Shares Are Trading Lower By 59%? 54 Stocks Moving In Friday's Mid-Day Session

Gainers Getty Images Holdings, Inc. (NYSE: GETY) shares jumped 106.7% to $21.69 after nearly 99.
benzinga.com
Stocks That Hit 52-Week Lows On Friday

  On Friday, 137 stocks made new 52-week lows.
benzinga.com
Stocks That Hit 52-Week Lows On Wednesday

  Wednesday's session saw 269 companies set new 52-week lows.
benzinga.com
Stocks That Hit 52-Week Lows On Monday

  During Monday's trading, 1214 companies set new 52-week lows.